Search bioRxiv⌕ Search

Biology subjects

High, A.

Publications and source records attributed to High, A..

3 recordsLinked to original sources

Lineage-mixed neurodevelopmental programs in pediatric sarcomas nominate tumor-selective surface antigen pairs.

Pediatric solid tumors have low mutational burden, frequent oncogenic gene fusions, and developmental origins in arrested progenitor cells. Single-cell RNA-seq (scRNA-seq) could represent an ideal tool to assess whether these convergent biological features yield shared therapeutic vulnerabilities. However, while existing tools can extract gene expression programs for pan-tumor single-cell data, interpreting them requires domain expertise across many disciplines and diseases. Here, we analyzed a pan-pediatric scRNA-seq atlas of 266 patient- and xenograft-derived samples across 22 pediatric solid tumor types. To address the bottleneck between gene program identification and interpretation, we developed an AI agent framework built on off-the-shelf large language models (e.g., Gemini 2.5) to interpret gene expression programs at the level of human experts, but at much greater scale and speed. Our agent identified ectopic expression of neuronal marker genes as a unique feature of several fusion-driven sarcomas. This gene expression pattern resulted in tumor-specific co-expression of mixed mesenchymal/neuronal surface markers, providing a plausible therapeutic window to target these tumor types using emerging AND-gated therapeutic strategies, such as bispecific antibody-drug conjugates (ADCs) and bispecific CAR-T cells. As proof of principle, we nominated and validated STEAP1/NPTXR as a Ewing sarcoma candidate cell surface target pair. Together, this work delivers a pan-pediatric solid tumor scRNA-seq atlas, establishes a generalizable and accessible AI-based framework that complements existing single-cell methods by automating interpretation of pan-disease single-cell atlases, and nominates new bispecific ADC/CAR-T targets for catastrophic pediatric cancers.

cancer biology↗

P. aeruginosa liquid-based pathogenesis triggers HLH-30-dependent metabolic rewiring in C. elegans

Innate immunity is the first line of defense against invading pathogens and is essential for maintaining host survival. While the majority of innate immunity studies have focused on pathogen recognition and antimicrobial responses, increasing evidence suggests that lipid metabolism plays a fundamental role in shaping immune function. Understanding how these metabolic pathways contribute to immunity is crucial in the context of bacterial infections caused by opportunistic pathogens such as Pseudomonas aeruginosa. Host defense against P. aeruginosa requires the coordination of innate immune and metabolic responses; however, the mechanisms linking lipid metabolism to pathogen resistance remain poorly understood. Research into the relationship between lipid homeostasis and innate immunity may reveal factors governing host-pathogen interactions and identify novel strategies to enhance resistance to infection. Here, we demonstrate that P. aeruginosa liquid-based pathogenesis (LK-Pa) triggers a shift in host metabolism which differs from the one observed in response to agar-based pathogenesis. Our bioinformatic analyses revealed a highly similar metabolic profile (enrichment of lipid metabolism) in worms exposed to LK-Pa or the iron chelator phenanthroline, suggesting a shared host response to iron deprivation. We further characterized the host genetic factors driving this metabolic shift and established their importance for host defense against LK-Pa as well as liquid-based pathogenesis by Gram-positive pathogens Enterococcus faecalis and Staphylococcus aureus. Notably, our results indicate that LK-Pa triggers host lipid droplet depletion, an upstream component that leads to increased {beta}-oxidation. Finally, we demonstrate that LK-Pa triggers repression of MXL-3 which results in HLH-30-dependent metabolic rewiring.

cell biology↗

Reprogramming CAR T-Cells with designed bioPROTACs

Gene editing has been used to enhance CAR T-cell function by disrupting negative regulators but has limitations. Here we show that de novo-designed generated targeted degraders (bioPROTACs) provide an alternative approach. Expression of bioPROTACs in CAR T-cells targeting DNMT3A, a key regulator of T-cell exhaustion, phenocopied gene knockout. Our reversible, non-gene editing approach provides a tunable strategy to reprogram T-cell fate which should be broadly applicable for next-generation cell therapies.

immunology↗